Disc Medicine
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average or in the bottom third on momentum — the strategy is out of it.
- Signal has read SELL for 2 months.
- Its last 6 Sell calls were actually followed by a +23% average gain three months out - this one has bounced back faster than the signal expected.
- Recent price momentum is -10.8% on average (3-month/1-year).
- Main-fund capital flow has been a net inflow over the last 45 sessions.
- Short interest has risen to 15.5% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and above its 60-day average.
- The 20-day average is above the 60-day average, a short-term uptrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2849 U.S. stocks StockVane covers.
Last computed: 2026-11-21 14:27 UTC
Data coverage: 4 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation N/A
How expensive the stock is versus earnings, sales and its own 5-year history.
Not enough data to grade this factor.
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability D-
How much profit the business keeps from each dollar of sales and capital.
| Return on equity | -35.9% | Better than 11% |
| Return on invested capital | -37.0% | Better than 8% |
Momentum B-
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -5.9% | Better than 60% |
| 6-month return | 12.5% | Better than 75% |
| 12-month return (ex latest month) | -19.0% | Better than 15% |
| Distance below 52-week high | 24.5% | Better than 52% |
Financial Health B+
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 21.9x | Better than 98% |
| Debt to assets | 3.8% | Better than 82% |
| Interest coverage | -57.7x | Better than 7% |
Analyst View A-
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 100.0% | Better than 77% |
| Upside to average target | 66.4% | Better than 74% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 76.11
- Open
- 75.20
- Day range
- 74.54 - 77.01
- Avg price
- 75.29
- Volume
- 561.65K
- Turnover
- 42.28M
- Turnover ratei
- 1.40%
- Volume ratioi
- 0.76
- Amplitudei
- 3.25%
- 52-week rangei
- 40.00 - 99.50
Valuation
- P/Ei
- -12.50
- P/E (TTM)i
- -11.85
- P/Bi
- 5.66
- EPSi
- -6.01
- Book value / shi
- 13.27
- Net profit
- -273.70M
- Net assets
- 604.24M
Share structure
- Market cap
- 3.42B
- Float capi
- 3.02B
- Shares out
- 45.54M
- Float sharesi
- 40.15M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 1970-01-01
24.5% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
+3.85M net over the window
Short interest
- Shares short
- 6.86M
- % of floati
- 15.46%
- Days to coveri
- 3.18
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Disc Medicine (IRON)?
Disc Medicine last traded at 75.14. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Disc Medicine's market cap?
About 3.42B.
What is the P/E ratio of Disc Medicine?
The trailing twelve-month P/E is -11.85. The Valuation tab shows it against the stock's own five-year range.
Does Disc Medicine pay a dividend?
Disc Medicine does not currently pay a regular dividend.
Is Disc Medicine a buy according to analysts?
The consensus of 10 analysts is a Buy rating, with an average 12-month price target of 125.00, which implies 66.4% upside from the current price. This is not investment advice.
What is Disc Medicine's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Disc Medicine a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.
Quote time 2026-11-20 20:01:18 · For reference only, not investment advice and not tailored to your situation.
Disc Medicine discussion 0 comments